Resource Use and Treatment Costs after Kidney Transplantation: Impact of Demographic Factors, Comorbidities, and Complications
EG Hagenmeyer,B Haussler,E Hempel,G Grannas,Z Kalo,A Kilburg,B Nashan
DOI: https://doi.org/10.1097/01.tp.0000121763.44137.fa
2004-01-01
Transplantation
Abstract:Background. Our goal was to quantify outcomes, resource use, and treatment costs for the first 2 years after renal transplantation in a "real-life" European setting and to assess the impact of preoperative risk factors and postoperative complications on treatment costs.Methods. Inpatient and outpatient records of all patients who received a renal transplant at Medizinische Hochschule Hannover, Germany, between January 1998 and July 2000, were evaluated. Key clinical events were recorded. Direct costs were calculated for primary hospitalization, the remainder of year 1, and year 2 after transplantation. Cost of organ procurement, pretransplant care, and transplant surgery were excluded. Cost consequences for key clinical events were determined.Results. Of 204 patients undergoing transplantation, 195 and 149 completed 1 year and 2 years of follow-up, respectively. The outcomes of years 1 and 2, respectively, were as follows: graft failure, 5.4%, 0.7%; acute rejection, 35.9%, 5.4%; cytomegalovirus (CMV) infection, 29.2%, 2.0%; and delayed graft function, 30.9%. Costs for primary hospitalization, the remainder of year 1, and year 2 averaged is an element of15,380, is an element of18,636, and is an element of14,484, respectively. Cost-driving events included graft failure is an element of36,228), acute rejection (is an element of9,638), delayed graft function (is an element of7,359), and CMV infection (is an element of4,149). Graft failure and acute rejection for year 1 also added significantly to the costs for year 2.Conclusions. These results show that posttransplant clinical outcomes result in a significant increase in treatment costs. Because the economic impact of primary causes of chronic rejection (acute rejection and CMV) and delayed graft function is substantial, careful selection of the most appropriate immunosuppressive regimen is essential.